Citations

Clear

2228 citation(s) found for "Le, Anne".

Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (RCTs)
Bullecer, Dorothy Lim, Mohammed, Cara, Loiola, Julie Anne de Lima, Chy, Mary Gabrielle Te, Ramli, Samratul Fuadah, Hussein, Abimbola, showkat, wasid bin, Taikadan, Thahsin, Mutyala, Sarika, Ahmad, Adeel, Alsubari, Asma’a Munasar Ali, Bullecer, Dorothy, Loiola, Julie de Lima , Ayyan, Muhammad , Rehman, Muhammad Aemaz Ur

Mayo Clinic

Brain and Behavior | June 1, 2026 | Volume: 16 | Issue: 6 | Pages: No page available

10.1002/brb3.71520 | PMID 42219764 Get It

ABSTRACT Background : Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes. The goal of this study is to assess the safety and efficacy of the drug in patients who have suffered an acute ischemic stroke. Methods : A comprehensive search of PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception to December 2025 yielded randomized controlled trials (RCTs) comparing Tirofiban and conventional management in patients with acute ischemic stroke. We assessed the risk of bias using the revised Cochrane “Risk of bias” tool for randomized trials (RoB 2.0). We analyzed the outcomes using RevMan 5.4, with risk ratio (RR) as the effect measure. Results : A total of 9 RCTs with 4210 patients were included in our meta‐analysis. According to our meta‐analysis, the tirofiban group was associated with a statistically significant increase in the patients showing functional independence at 90 days, measured by patients with Modified Rankin Score (mRS) of 0–2 (RR 1.13; CI = 1.06–1.20) and excellent outcome (mRS score 0–1) at 90 days (RR 1.17; CI = 1.05–1.29). We found no statistically significant difference between the two groups regarding mortality (RR 0.94; CI = 0.63–1.40). The tirofiban group had an increased incidence of intracranial hemorrhage (ICH) (RR 1.25; CI = 1.06–1.47) but had a similar incidence of symptomatic ICH as compared to the control group (RR 1.48; CI = 0.98–2.24). Conclusion : This meta‐analysis suggests that tirofiban may improve favorable functional outcomes (mRS 0–2) in acute ischemic stroke, although the certainty of evidence was moderate. While no significant increase in sICH was observed, some analyses showed a higher rate of overall intracranial hemorrhage. These findings should therefore be interpreted cautiously, and further high‐quality randomized trials are needed to confirm the efficacy and safety of tirofiban before routine guideline use.
Current State and Needs of Clinical Laboratories in Selected Countries in Africa
Tesfazghi, Merih, Tebo, Anne E. , Harb, Roa , Okorodudu, Anthony O. , Schroeder, L, Guarner, Jeannette , Bales, Christine, Ladenson, Jack, Targowski, Allison, Cosby, Kerry, Oladipo, Olajumoke, Tesfazghi, Merih T. , Ladenson, Jack H., Oladipo, Olajumoke O.

Mayo Clinic

The Journal of Applied Laboratory Medicine | May 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jalm/jfag089 | PMID 42335177 Get It

Abstract The Africa Working Group, under the auspices of the Global Laboratory Quality Initiative of the Association for Diagnostics & Laboratory Medicine (ADLM), conducted several educational workshops in Africa to promote laboratory quality in the region. The challenges faced in maintaining quality in clinical laboratories in low-resource countries may differ from region to region and country to country. To better understand current gaps and inform our engagement with partners in Africa, a needs assessment survey was distributed to 1427 ADLM members in Africa and further disseminated through local partners, resulting in 121 responses from participants across 8 countries in the region. Additionally, interviews were conducted with laboratory professionals from the countries surveyed. The surveys primarily focused on quality management, continuing education, budgeting, infrastructure and funding, supplies, and staffing issues. The data collected from the surveys and interviews strongly indicate that respondents face major challenges in all areas assessed, including lack of funding, lack of equipment, lack of quality control (QC) and external quality assessment (EQA) materials, gaps in quality management, lack of appropriate budgeting, staffing issues, and lack of accessible training/continuing education. Consistent with the primary focus of ADLM;s Global Quality Initiative, improved access to continuing education was identified as the primary need by the participants (58%). The assessment highlights that while a strong role for educational workshops in mitigating some of the challenges continues to exist, there is also an opportunity to broaden the scope of the working groups beyond education.
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Wechalekar, Ashutosh , Sanchorawala, Vaishali , Zepeda, Victor H. Jimenez-, Suzuki, Kenshi, Lentzsch, Suzanne , Huart, Antoine , Carpinteiro, Alexander , Swenson, Eugene , Khan, Zilehuma, Catini, Julia, Kulkarni, Hrishikesh, Meltzer, Brian, Lake, Stephen, Liedtke, Michaela , Investigators, for the CARES, Ting, Stephen Bek Ngie, Mollee, Peter Norman, Meuleman, Nathalie, Delforge, Michel, Zepeda, Victor Jimenez, Zhang, Shuyang, Du, Xin, Wang, Jianan, Qian, Honglan, Sun, Chunyan, Belhadj, Karim , Arnulf, Bertrand, Karlin, Lionel, Macro, Margaret, Colella, Jean-Marc Schiano De, Stoppa, Anne-Marie, Viallard, Jean-Francois, Fenk, Roland, Hansen, Timon, Girke, Vera, Nogai, Axel, Gatt, Moshe, Lavi, Noa, Magen, Hila , Palladini, Giovanni, Pane, Fabrizio, Buda, Gabriele , Ishida, Tadao, Iida, Shinsuke, Jamroziak, Krzysztof, Byun, Jamin, Koh, Youngil, Kim, Kihyun, Villamediana, Ramón Lecumberri, Lopez, Maria Teresa Cibeira, Martínez, Irene Romera, Duarte, Rafael , Castello, Isabel Angela Krsnik, Garcia, Maria Esther Gonzalez , Chacon, Eusebio Narciso Martin, Martínez, Javier Alberto Rojas , Valent, Jason , Rosenzweig, Michael A., Chung, Alfred, Wong, Sandy, Bumma, Naresh , Comenzo, Raymond, Gaballa, Mahmoud, Lee, Hans C., Kaufman, Gregory P., Passero, Frank, Stockerl-Goldstein, Keith, Waxman, Adam, D'Souza, Anita, Cowan, Andrew, Lee, Sarah, Libby, Edward, Godara, Amandeep , Kovacsovics, Tibor, Sengsayadeth, Salyka, Goodman, Stacey , Chaulagain, Chakra, Wechalekar, Ashutosh D. , Dispenzieri, Angela , Sanchorawala, Vaishali , Kastritis, Efstathios , Lentzsch, Suzanne , Meltzer, Brian , Liedtke, Michaela , Dispenzieri, Angela , Kastritis, Efstathios , Bhutani, Divaya , Bianchi, Giada , Suzuki, Kenshi , Khan, Zilehuma, Kulkarni, Hrishikesh, Lake, Stephen, Ting, Stephen B. , Mollee, Peter , Agis, Hermine , Straßl, Irene , Meuleman, Nathalie , Delforge, Michel , Sedlák, František , Jaccard, Arnaud , Arnulf, Bertrand , Karlin, Lionel , Macro, Margaret , Stoppa, Anne‐Marie, Bridoux, Frank , Chalopin, Thomas , Viallard, Jean‐François , Fenk, Roland , Symeonidis, Argiris , Annibali, Ombretta , Iida, Shinsuke, Ikezoe, Takayuki , Jamroziak, Krzysztof , Koh, Youngil, López, Maria Teresa Cibeira, Rios, Rafael, Garcia, Maria Esther Gonzalez, Chacón, Eusebio Martín, Valent, Jason Neil , Rosenzweig, Michael, Comenzo, Raymond L. , Gaballa, Mahmoud , Kaufman, Gregory P., Medvedova, Eva , Passero, Frank Charles , Stockerl-Goldstein, Keith , Chaulagain, Chakra P.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2026 | Volume: 44 | Issue: 20 | Pages: 1899-1910

10.1200/jco-26-00755 | PMID 42212672 Get It

PURPOSE In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance. METHODS Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation. RESULTS Among 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50; P = .332) and the hazard ratio (HR) for ACM was 0.80 (95% CI, 0.57, 1.13; P = .290). CVH rates in the anselamimab and placebo groups were 0.59 (95% CI, 0.42, 0.83) and 0.89 (95% CI, 0.55, 1.43), respectively ( P = .145). Among patients with kappa isotype (n = 72), the win ratio was 2.06 (95% CI, 0.98, 4.31; P = .100) and anselamimab reduced ACM by 62% versus placebo (HR, 0.38; 95% CI, 0.17 to 0.86; nominal P = .012), and CVH by 71% (IRR, 0.29; 95% CI, 0.10 to 0.87; nominal P = .028) with improvements in Kansas City Cardiomyopathy Questionnaire-Overall Score. There was no clinical benefit observed in the lambda population. Anselamimab was generally well-tolerated; safety data were comparable between treatment arms overall. CONCLUSION Treatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.
Immune effector cell–associated enterocolitis (IEC-EC) incidence and characterization in cilta-cel–treated patients with RRMM in CARTITUDE clinical studies.
Lin, Yi, Tian, Shaozhou K. , Montgomery, Elizabeth, Roeloffzen, W, Jin, Jie, Sun, Huabin, Plaks, Vicki , Li, Katherine , Jablow, Lee, Sharma, Mukta, Singh, Preeti, Patel, Nitin , Lee, Erin, Sharma, Bhawna, Anguille, S, Minnema, Monique, Montgomery, Elizabeth Anne , Khan, Abdullah , Rocchi, Serena , Zamagni, Elena , Jin, Jie , Lee, Erin, Anguille, Sébastien , Minnema, Monique C , Strouse, Christopher

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7533-7533

10.1200/jco.2026.44.16_suppl.7533 Get It

7533 Background: Ciltacabtagene autoleucel (cilta-cel) shows benefit for patients (pts) with relapsed/refractory multiple myeloma (RRMM). A recently recognized uncommon adverse reaction, IEC-EC is characterized by severe/persistent diarrhea typically 1–3 months post CAR-T cell infusion. Here we summarize incidence and features of IEC-EC in clinical trials of cilta-cel for RRMM. Methods: 483 pts across RRMM studies (CARTITUDE-1, -2, -4, and CARTIFAN-1) were evaluated for evidence of IEC-EC. The clinical picture and nomenclature for IEC-EC were described in the real-world setting after infusion of most pts. As such, retrospective analysis was performed to identify cases consistent with IEC-EC, defined as prolonged (≥3 weeks) and severe (≥grade 3) diarrhea after cilta-cel infusion, without clear infectious etiology. Correlative biomarker analyses included peripheral CAR-T cell expansion/persistence, immune cell composition, and cytokines/inflammatory markers. Centralized pathomorphological review and immunohistochemical analysis of available biopsies was conducted. Results: Across RRMM studies, 6/483 (1.2%) pts demonstrated the clinical picture of IEC-EC, presenting 12–214 days after receiving cilta-cel (median onset 67 days post infusion). Best response was CR/sCR for all subjects. Pts received therapies including steroids (4/6). Four pts experienced symptom resolution within 123–227 days; 2 had persistent symptoms until death (causes: multiorgan failure and COVID19). Pts with IEC-EC had lower levels of B cells and higher levels of CAR+ T cells and inflammatory cytokines (eg, IL-6) at onset compared to a GI symptom-free control group at comparable time; while all cilta-cel–treated pts experienced B cell depletion, pts with IEC-EC had more prolonged deficiency. Histological analyses of GI biopsies from 5 pts with IEC-EC revealed plasma cells, normally present in the GI tract, were absent. CAR-T cells were detected and localized to the lamina propria and were not observed juxtaposed with epithelia, making it unlikely direct damage to epithelia was caused by CAR-T cells. Histologic damage was greater in the small intestine (predominantly duodenum) than the colon. Conclusions: Retrospective analysis of cilta-cel trials identified a low IEC-EC incidence (1.2%). Findings support a reactive mechanism involving plasma cell depletion and immune dysregulation rather than direct CAR-T cell cytotoxicity and highlight the importance of upper endoscopy to identify injury patterns in the small intestine that may be less pronounced in the colon. Although the pathophysiology is not fully defined, increased awareness and earlier diagnosis may improve understanding of management and enhance likelihood of IEC-EC reversibility.
Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.
Ruddy, Kathryn Jean, Ginos, Brenda, Heiling, Hillary, Rogak, Lauren , Atanasov, Stafan S., Sinclair, Sarah, Fenton, Mary Anne, Muss, Hyman, Sinclair, Natalie, Hamilton, Erika P., Dang, Chau T., Faggen, Meredith, Lo, S., Mitchell, Sandra A., Winer, Eric P., Dueck, Amylou C., Ruddy, Kathryn J. , Heiling, Hillary , Sedrak, Mina S. , Atanasov, S., Sinclair, Sarah , Mortimer, Joanne , Fenton, Mary Anne , Sinclair, Natalie, Lo, Steve, Mitchell, Sandra A , Winer, Eric P. , Dueck, Amylou C. , Freedman, Rachel A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 635-635

10.1200/jco.2026.44.16_suppl.635 Get It

635 Background: Prospective data on efficacy, quality of life, and treatment-related toxicities in older adults with breast cancer are limited. The ATOP trial (NCT03587740) evaluated T-DM1 in older adults and demonstrated favorable 5-year invasive disease-free survival. Here, we report patient-reported adverse events (AEs) and health-related quality of life (HRQOL) findings from ATOP. Methods: ATOP was a single-arm, phase II, multicenter study of adjuvant T-DM1 for those aged 60 with stage I-III HER2+ breast cancer. Protocol therapy included postoperative administration of T-DM1 (3.6 mg/kg) every 21 days for one year (17 cycles). PRO-CTCAE (assessing specific symptoms) and EQ-5D (a measure of HRQOL) surveys were administered electronically or on paper at baseline (pre-treatment), on Day 1 of each treatment cycle, and at a single 6–12-month post-treatment time point. Participants who responded to the baseline and at least one follow-up survey were included in the PRO analysis. EQ-5D changes from baseline were assessed using general linear mixed models. Summary statistics were used to assess PRO-CTCAE scores to evaluate which symptoms developed between baseline and 1 subsequent survey(s) and their severity. Results: Among the 111 patients enrolled on ATOP (median age=71, range 60-88 years), 98 responded to the baseline survey and 1 subsequent survey(s). 1435 surveys were returned that included at least one PRO-CTCAE response, and 1661 surveys were returned that included EQ-5D. The Table displays the % of participants who reported PRO-CTCAE symptoms that worsened from baseline to any severity level (scores >0) or to a severe level (scores ≥3). More than 60% of survey respondents reported new or increased dry mouth, fatigue, muscle aches, decreased appetite, nausea, pain, and/or numbness/tingling at some point during or after treatment, but these were usually not severe. EQ-5D scores did not change significantly from baseline at any time point. Conclusions: In this adjuvant trial for patients aged >60, participation rates for PRO data collection were high. Reassuringly, global HRQOL was not impacted by T-DM1, and though frequently reported, the vast majority of patient-reported symptoms were mild. Future analyses of this trial will focus on duration and predictors (clinical and biomarker-based) of severe AEs, agreement between patient-reported and clinician-reported AEs, and whether sharing PRO reports with clinicians impacted clinician-reported AE grades. Clinical trial information: NCT03587740 . Most common new or worsening symptoms reported via PRO-CTCAE in ATOP (n=95). Symptom % with score >0 n (%) with score 3+ Dry mouth 79% 26% Fatigue 71% 29% Muscle aches 69% 20% Decreased appetite 69% 12% Nausea 67% 6% Pain 66% 21% Numbness/tingling 65% 9% Blurry vision 60% 4% Mouth or throat sores 60% 5%
Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.
Isaacs, C, Howard-Mcnatt, Marissa, Yau, C, Chien, Jo, Wallace, Anne M., Han, Hyo S., Yee, D, Omene, Coral, Nanda, Rita, Chapple, Andrew, Perlmutter, J, Pohlmann, Paula R., Borowsky, Alexander D., Symmans, W. Fraser, Veer, Laura van't, Esserman, L J, Pohlmann, Paula R. , Pohlmann, Paula , Yeung, Kay T. , Isaacs, Claudine , Howard-McNatt, Marissa Michelle , Yau, Christina , Boughey, Judy C. , Han, Hyo S , Borges, Virginia F. , Falkson, Carla I. , Yee, Douglas , Omene, Coral , Nanda, Rita , Symmans, W. Fraser

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 625-625

10.1200/jco.2026.44.16_suppl.625 Get It

625 Background: I-SPY 2 is a multicenter phase II adaptive platform trial evaluating novel agents for stage II-III high-risk breast cancer using response-predictive subtypes (RPS) and a sequential neoadjuvant treatment design of up to three blocks (A/B/C). Investigational regimens are given in Block A, followed by response-guided escalation to standard-of-care (SOC) therapy (tx) in subsequent blocks or early surgery for responders. Topoisomerase I (TOPO1) inhibition plus PARP inhibition may enhance DNA damage and tumor response. DAN-222 is a tumor-targeted polymeric camptothecin conjugate designed to improve the therapeutic index of TOPO1 inhibition. Based on favorable phase 1 safety and preliminary activity in metastatic breast cancer, DAN-222 plus niraparib was evaluated as Block A tx in HER2− disease. Notably, the neoadjuvant regimen used a higher dose of niraparib (200 mg daily) than the prior phase 1 metastatic study. Methods: Patients (pts) with HER2− breast cancer were randomized to DAN-222 plus niraparib for up to 12 weeks in Block A. Response was assessed by serial MRI and biopsy. Inadequate responders escalated early to SOC tx in Blocks B/C. Primary endpoint was pathologic complete response (pCR). Secondary endpoints included residual cancer burden, safety, early discontinuation, and treatment-strategy performance versus subtype-specific SOC tx controls. Given established PARPi sensitivity in BRCA mut disease, the key objective was to assess clinically meaningful activity of DAN-222 plus niraparib in BRCA wt pts. Accordingly, a prespecified Bayesian interim futility analysis focused on BRCA wt and tested the probability of the true pCR rate after Block A alone exceeded 15% after 50 pts. Results: Fifty pts enrolled from Sep to Dec 2024. In BRCA wt (n=47), estimated Block A pCR was 3%, with posterior probability of 0.02 that that true pCR exceeded 15%, meeting futility criteria and prompting arm closure. Across all blocks, pCR rate was 57% (8/14) for HR-HER2−; 11% (4/36) for HR+ HER2−, largely after SOC tx. 2/3 BRCA mut pts achieved pCR. Treatment strategies initiating with DAN-222 plus niraparib underperformed subtype-specific controls. 68% discontinued Block A early, mainly due to toxicity. Grade ≥3 cytopenias were common: neutropenia (n=25; 50%), anemia (24%), and thrombocytopenia (18%). Cystitis occurred in 36% (1 grade ≥3). Conclusions: Neoadjuvant DAN-222 plus niraparib showed insufficient activity and no treatment-strategy benefit in BRCA wt HER2− breast cancer, underscoring challenges for TOPO1–PARP inhibitor combinations. Although not supported for further development in this setting, these results highlight the strength of I-SPY 2 in rapidly enrolling patients and quickly distinguishing ineffective from promising therapeutic strategies to accelerate progress toward improved outcomes for patients with curable breast cancer. Clinical trial information: NCT01042379 .
Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
Mahalingam, Devalingam, Shroff, Rachna, Carneiro, Benedito A., Ji, Yan, Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Loconte, N, Percent, Ivor John, Lopez, Charles D., Pernot, Simon, Kavan, Petr, Mulcahy, Mary Frances, Giles, Francis J., Mazar, Andrew P. , Jaros, Mark, Bekaii-Saab, T., Sahai, Vaibhav , Mahalingam, Devalingam , Shroff, Rachna T. , Carneiro, Benedito A. , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Percent, Ivor , Lopez, Charles D. , Pernot, Simon , Kavan, Petr , Mulcahy, Mary F. , Carr, Ryan M , Bekaii-Saab, Tanios S

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4213-4213

10.1200/jco.2026.44.16_suppl.4213 Get It

4213 Background: Elraglusib (9-ING-41), a glycogen synthase kinase-3β (GSK-3β) inhibitor, has multimodal antitumor activity. In the international, open-label, randomized phase 2 1801 Part 3B study, elraglusib plus gemcitabine/nab-paclitaxel (GnP) was evaluated in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC), with patients randomized 2:1 to weekly elraglusib/GnP or GnP alone. Primary endpoints were median overall survival (mOS) and 1-year survival. The GnP control arm demonstrated shorter mOS than contemporary randomized trials (7.2 months vs 9.2 months in NAPOLI-3 and 9.7 months in PASS-01), driven by higher early mortality (0–2 months: 23.1% vs 10.1% in NAPOLI-3). Given balanced randomization, similar early mortality was inferred in the elraglusib/GnP arm, prompting post-hoc analyses to contextualize efficacy and identify factors associated with early death. Methods: Efficacy and safety were summarized descriptively. Time-to-event endpoints were analyzed using Kaplan–Meier estimates, log-rank testing, and Cox proportional hazards models. Response rates were compared using the Cochran–Mantel–Haenszel test. Post-hoc subgroup, sensitivity, and machine-learning–based multivariate analyses explored clinical, demographic, and biomarker correlates of survival and early mortality. Results: In the full randomized population (elraglusib/GnP n=155; GnP n=78), elraglusib/GnP improved mOS by 2.9 months versus GnP (10.1 vs 7.2 months; HR 0.62; 95% CI 0.46–0.84; p=0.01), with 1-year survival rates of 44.1% versus 22.3%. Among patients receiving ≥1 full treatment cycle, mOS was 12.5 months with elraglusib/GnP and 8.5 months with GnP, comparable to contemporary registrational trials. Across multiple post-hoc sensitivity analyses—including evaluable patients, those matched to NAPOLI-3 baseline tumor burden, patients treated in the EU (early mortality 4%), and those achieving ≥20% CA19-9 decline within the first 1–2 cycles—elraglusib/GnP consistently demonstrated a ≥4-month OS advantage. Early death was associated with low baseline albumin (<3 g/dL), high CA19-9 (>800 U/mL), high tumor burden, and KRAS, TP53, and CDKN2A co-mutations. Conclusions: The elevated early mortality in the GnP control arm reflects enrollment of a heterogeneous, real-world mPDAC population with less restrictive eligibility than recent registrational trials. Post-hoc analyses identify key clinical and molecular drivers of early death and confirm a consistent survival benefit with elraglusib/GnP. These hypothesis-generating findings directly inform eligibility criteria, stratification, and endpoint assumptions for the planned phase 3 trial. Clinical trial information: NCT03678883 .
Hyaluronan Regulates Vascular Smooth Muscle Cell Osteogenic Differentiation and Vascular Calcification
Roy, Shrea, Kane, Jamie, Grigorieva, Irina, Roche-Dugmore, Dylan , Moore, Sacha , Steadman, Robert , Raby, Anne‐Catherine , Schurgers, Leon, Lutgens, Esther, Eringa, Etto C. , Vervloet, Marc , Fraser, Donald , Meran, Soma , Kane, Jamie , Schurgers, Leon J. , Kane, Jamie , Schurgers, Leon , Eringa, Etto C , Vervloet, Marc G , Fraser, Donald , Jakulj, Lily , Lutgens, Esther

Mayo Clinic

Biomolecules | May 22, 2026 | Volume: 16 | Issue: 5 | Pages: 729

10.3390/biom16050729 | PMID 42194078 Get It

Vascular calcification is a strong predictor of cardiovascular mortality and lacks effective treatment. The transformation of vascular smooth muscle cells (VSMCs) into osteoblast-like phenotypes is a key driver of calcification. This study identifies a regulatory role for Hyaluronan (HA) in VSMC osteogenic differentiation and arterial calcification. Human aortic VSMCs stimulated with high phosphate and/or pro-inflammatory cytokines (IL6 and TGF-β1) exhibited increased RUNX2, alkaline phosphatase and osteopontin expression, along with reduced contractility and elevated calcium deposition. This corresponded with reduced HA deposition and downregulation of HA synthase enzymes (HAS1, HAS2), Hyaluronidase enzymes (Hyal1), and HA binding proteins (CD44, TSG-6), whilst HAS3 and versican were upregulated. Comparable alterations in HA and protein expression were observed in an in vivo model of arterial calcification using vitamin K-deficient warfarin-fed mice. Pharmacological inhibition of HA synthesis, enzyme-mediated HA degradation and siRNA/plasmid modulation of HAS isoenzymes demonstrated a possible functional link between HA regulation and VSMC osteogenic differentiation. This study establishes HA and its associated binding proteins as key regulators of arterial calcification, highlighting a novel pathway for potential therapeutic intervention.
Role of the Emergency Medicine Pharmacist in the Management of Boarding Patients: An Opinion of the Emergency Medicine Practice and Research Network of the American College of Clinical Pharmacy Endorsed by the SAEM Academy of Emergency Medicine Pharmacists
Gilbert, Brian W. , Zimmerman, David E. , Robertson, Alyssa , Jones, Gavin D. , Gendron, Bryan J. , Corio, Jessica L. , Harlan, Sarah S. , Engstrom, Kellyn , Maisenbach, Alexa , Rambaran, Kerry Anne , Mercer, Kevin , Geier, Curtis , Truoccolo, Donna Shuler , Blue, Heather , Mercer, Kevin , Feldman, Ryan , Geier, Curtis , Truoccolo, Donna Shuler , Weant, Kyle A , Blue, Heather , Harlan, Sarah Schuman

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 21, 2026 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/jac5.70227 | PMID 42161376 Get It

ABSTRACT As emergency department (ED) crowding and patient boarding reach critical levels nationwide, the role of the emergency medicine pharmacist (EMP) must be both defined and safeguarded. While EMPs are increasingly valued for their contributions to acute care, their responsibilities often unintentionally expand during periods of operational strain, particularly when admitted patients remain in the ED for prolonged durations. EMPs should ideally be resourced to remain focused on time‐sensitive, high‐risk medication management where their expertise is most impactful and not be used as default providers for all pharmacotherapy needs during ED boarding. This perspective outlines our position on the ideal scope of EMP practice during times of congestion, advocating for clearly defined role boundaries, strategic collaboration with other pharmacy team members, and system‐level support to prevent dilution of emergency care. EMPs must be empowered to prioritize critical ED workflows, support resuscitations, and lead initiatives in education, protocol development, and patient safety, without being overextended by responsibilities that can be absorbed by other team members.
Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic
Patel, Shyam A. , Zhu, Valerie, Gerber, William K , Suzuki, Sakiko , Barker, Charlotte, Hutchinson, Lloyd, Khedr, Salwa, Cachia, David , Mangaonkar, Abhishek A. , McGuiness, Matthew, Higgins, Anne W. , Miron, Patricia M., Gerber, Jonathan M., Patel, Shyam A , Hutchinson, Lloyd, Khedr, Salwa , Miron, Patricia Minehart , Gerber, Jonathan M.

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1915-1927

10.1002/ajh.70374 | PMID 42157378 Get It

ABSTRACT Age‐related changes in human hematopoietic stem cells (HSCs) often form the basis for clonal hematopoiesis (CH), which presages the development of overt myeloid neoplasm with variable risk. CH can also arise after exposure to chemotherapy, radiotherapy, or immune interventions. In this study, we performed clinico‐genomic profiling of therapy‐related CH (t‐CH) ( n = 67) versus de novo CH ( n = 123) from a multidisciplinary CHIP Clinic. The most enriched mutations in t‐CH were TET2 (26.2%), DNMT3A (22.4%), and TP53 (8.4%). Median latency period from the time of initial exposure to the diagnosis of t‐CH was 6.96 ± 1.10 years. Patients with t‐CH had inferior event‐free survival compared to de novo CH (median 29.9 months versus 122.1 months, p = 0.0045). Overall survival was also shorter in t‐CH versus de novo CH (median 55.3 months vs. 129.2 months, p = 0.043). Genes that imparted significantly increased risk for progression from t‐CH to overt therapy‐related myeloid neoplasm (t‐MN) included JAK2 (relative risk (RR) 9.42, p = 0.0001), RUNX1 (RR 7.11, p = 0.001), EZH2 (RR 7.11, p = 0.001), and TET2 (RR 13.4, p = 0.01). Clonal dynamic modeling of patients with t‐CH who progressed to overt t‐MN showed an increase in the relative clonal fraction and new clonal outgrowth. In the t‐CH cohort, higher mean variant allele frequency was observed in progressors versus non‐progressors (77.1% vs. 30.6%, p = 0.017). This study sheds light onto outcomes for CH based on differing clinical ontogeny and has implications for previvorship for secondary malignancies.